INTRODUCTION
============

The pituitary adenylate cyclase-activating polypeptide (PACAP) is widely expressed in the nervous system and regulates several physiological functions, including neuronal and pheochromocytoma cell differentiation ([@B9]; [@B48]), axonal and dendritic growth, and neuronal survival ([@B66]). These actions are mediated by the activation of seven transmembrane receptors, including both the high-specificity type I PACAP receptor (PACR1) and the type II receptors (VPAC1 and VPAC2) ([@B65]; [@B59]). Although a comprehensive understanding of the signal transduction network mobilized by these receptors is lacking, activation of adenyl cyclase and regulation of mitogen-activated protein (MAP) kinase signaling pathways play prominent roles in the biological actions of PACAP ([@B24]; [@B48]; [@B56]; [@B12]). Although cAMP can induce PC12 cell differentiation ([@B15]), and cAMP signaling has been classically associated with activation of protein kinase A (PKA), the neurotrophic effects of PACAP do not rely solely upon PKA signaling. Instead, recent studies have identified the exchange protein activated by cyclic AMP (Epac) guanine nucleotide exchange factors (GEFs) as crucial mediators of PKA-independent cAMP signaling ([@B5]; [@B51]). Indeed, Epac proteins are required for PACAP-mediated differentiation signaling ([@B24]; [@B56]), acting to link G~s~α-coupled receptor signaling to MAP kinase cascade activation in neurons ([@B32]; [@B24]).

Recent studies have identified the Rit small guanosine triphosphate (GTP)-binding protein as regulating cellular signaling pathways critical to neuronal differentiation ([@B1]; [@B53]; [@B56]). Rit is expressed in the majority of adult and embryonic tissues, including a variety of primary neurons and the developing brain ([@B27]; [@B69]; [@B60]; [@B30]), and it shares a unique effector domain with the closely related Rin and Drosophila Ric proteins ([@B69]; [@B52]; [@B16]). Rit is activated after nerve growth factor (NGF) and PACAP stimulation, and RNA interference (RNAi)-mediated silencing of endogenous Rit inhibits NGF- and PACAP-mediated neurite outgrowth in pheochromocytoma cells ([@B61]; [@B53]; [@B56]). Rit signaling also seems to control neuronal morphogenesis, by both inhibiting dendritic and promoting axonal growth ([@B30]; [@B2]). Additional studies indicate that Rit signaling plays a central role in morphological events as diverse as BMP7-mediated dendritic growth ([@B30]) and interferon-γ--mediated dendritic retraction ([@B2]). Despite the importance of understanding the regulation of Rit signaling, to date no known Rit regulatory factors (GEFs or GTPase activation proteins \[GAPs\]) have been characterized. Thus, although modulation of the activation status of Rit may represent a generalized mechanism for regulating axonal versus dendritic growth modes ([@B22]; [@B30]; [@B2]), as well as neuronal survival ([@B60]), the underlying regulatory machinery remain uncharacterized.

G protein-coupled receptors (GPCRs) are known to use two general signaling mechanisms to exert their biological effects ([@B37]). Classical signaling involves the activation of canonical G protein-activated effector pathways. For PACR1, these include stimulation of adenyl cyclase, phospholipase C, phosphatidylinositol 3-kinase, and MAP kinase pathways ([@B48]; [@B12]). Recent work has established a second general signaling cascade that involves transactivation of a subset of receptor tyrosine kinases (RTKs) ([@B28]; [@B68]; [@B7]). For example, the TrkA receptor tyrosine kinase is activated directly by nerve growth factor (NGF) binding, but it is also involved in the activation of MAP kinase and Akt pathways by the PACR1 receptor ([@B28],[@B29]). On ligand activation, several intracellular tyrosine residues become phosphorylated on TrkA ([@B21]). In turn, Trk receptors phosphorylate and activate signaling proteins through the recruitment of proteins to specific phosphotyrosine residues ([@B21]). PACAP induces tyrosine phosphorylation of Trk receptors in a Src family kinase-dependent but neurotrophin-independent manner ([@B28],[@B29]). Thus, PACAP-mediated neuronal signaling involves both RTK-independent and RTK-dependent pathways. However, a comprehensive understanding of PACAP-mediated transactivation signaling is lacking, and therefore the physiological importance of signal integration between GPCR- and RTK-dependent pathways awaits further characterization.

We have previously demonstrated that Rit signaling plays a critical role in the neurotrophic effects of PACAP38 ([@B56]) and that PACAP-induced Rit activation involves a novel cAMP-Epac signaling cascade ([@B56]). However, Epac was not a direct Rit GEF, suggesting that an additional regulatory protein(s) was necessary to couple Epac signaling to Rit activation. In the present study, we report that PACAP-mediated Rit activation involves Epac-Src kinase-dependent transactivation of the Trk RTK. A single tyrosine (Y^499^) phosphorylation event within TrkA was identified as critical to Rit activation. Together with our previous observations, these results suggest that transactivation of a novel Trk-Rit signaling cascade plays a critical role in PACAP-mediated neuronal differentiation signaling.

MATERIALS AND METHODS
=====================

Plasmids and Reagents
---------------------

Rit ([@B56]) and Gα subunit expression vectors ([@B55]) have been described previously. Constitutively active Epac2 ([@B31]) and constitutively active SOS1 ([@B44]) were provided by Dr. L. A. Quilliam (Indiana University School of Medicine, Indianapolis, IN), whereas hemagglutinin (HA)-tagged wild-type rat TrkA and its mutants (TrkA \[Y499F\] and \[Y794F\]) were provided by Dr. S. Meakin (Roberts Research Institute, London, ON, Canada). Human Shc1 and Grb2 were purchased from Origene (Rockville, MD). Dominant-negative mutants of Shc1 (Shc1-FFF \[Y239F/Y240F/Y317F\]; [@B47]; [@B39]) and Grb2 (Grb2-R86K) ([@B58]; [@B20]) were generated using the QuikChange II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA). Antibodies against the following targets were purchased: FLAG (Sigma-Aldrich, St. Louis, MO); TrkA and anti-phosphotyrosine (Millipore, Billerica, MA); and SOS1, SOS2, C3G guanine-nucleotide exchange factor (C3G), c-Src, and actin (Santa Cruz Biotechnology, Santa Cruz, CA). The Src kinase inhibitor PP2 and its inactive analogue PP3, 2′,5′-dideoxyadenosine (ddA), adenosine 3′,5′-cyclic monophosphorothioate, adenosine 3′,5′-cyclic monophosphorothioate, Rp-isomer (Rp-cAMP), 8-(*p*-chlorophenylthio)-2′-*O*-methyl-adenosine-3′,5′-cyclic monophosphate (8-CPT-2-Me-cAMP), and cholera toxin (CTX) were purchased from Calbiochem (San Diego, CA), whereas pertussis toxin (PTX) was from Sigma-Aldrich.

Cell Lines, Cell Culture, and Transfection
------------------------------------------

PC6 cells (provided by Dr. T. Vanaman, University of Kentucky, Lexington, KY) were maintained as described previously ([@B60]; [@B53]). Nnr5 cells are a subline of PC12 cells that fail to express TrkA receptor (a kind gift from Dr. C. Wu, Stanford University, Palo Alto, CA; [@B14]; [@B6]). Nnr5 cells were cultured in DMEM supplemented with 10% (vol/vol) horse serum and 5% fetal bovine serum (FBS) (vol/vol), 100 μg/ml streptomycin, and 100 U/ml penicillin at 37°C in a humidified atmosphere of 5% CO~2~. NIH-3T3 cells were obtained from American Type Culture Collection (Manassas, VA) and maintained in DMEM supplemented with 10% (vol/vol) FBS, 100 μg/ml streptomycin, and 100 U/ml penicillin at 37°C in a humidified atmosphere of 5% CO~2~. PC6 cells and nnr5 cells were transfected with Effectene (QIAGEN, Valencia, CA) as described previously ([@B53]) or with DharmaFectDuo reagents (Dharmacon RNA Technologies, Lafayette, CO), whereas NIH-3T3 cells were transfected using SuperFect (QIAGEN) ([@B53]) or DharmaFectDuo reagents. Although both nnr5 and NIH-3T3 cells lack TrkA receptor expression, NIH-3T3 cells display higher transfection efficiency and were used to examine TrkA signaling.

RNA Interference
----------------

The mammalian expression vector pSUPER-GFP/Neo (Oligoengine, Seattle, WA) was used for expression of small interfering RNA (siRNA) as described previously ([@B53]; [@B55]). The gene-specific insert sequence of rat SOS2-3434 (AGTTCCTCCTCCGCTTCCC \[target sense\]) was synthesized and then subcloned to generate pSUPER-shSOS2-3434 (shSOS2-3434). Other rat target sense sequences used in this study include shSOS1-4316, CCTTTACACCGCCACCTCC; shPACR1-384, CTACTTCGATGCTTGTGGG; shC3G-128, AGCCCTCTCCTCTTGCTAT; shC3G-2739, GAACCTCCATGTATCCCAT; and a siRNA with no predicted target site in the rat genome (Scramber, shCTR; [@B53]) and a shEpac1-1501 that silences Epac1 expression ([@B56]). The resulting constructs were verified by DNA sequencing. To silence SOS1 expression, an On-Target plus SMARTpool of siRNA duplexes directed to rat SOS1 (siSOS1) was purchased from Dharmacon RNA Technologies, whereas an ON-TARGET*plus* nontargeting siRNA (siCTR) was used as negative control. To determine the effects of shSOS or shC3G on the expression of endogenous SOS or C3G proteins, PC6 cells were transfected with of shSOS1-4316, shSOS2-3434, shC3G-128, shC3G-2739, or shCTR as control (1.5 μg), and then they were subjected to G418 selection (400 μg/ml) for 60 h to enrich for transfected cells. To determine the efficiency of SOS1 silencing or double knockdown of both SOS1 and SOS2 proteins mediated by siRNA, PC6 cells were transfected with either siCTR or siSOS1 (20 nmol of siRNA duplex final; Dharmacon RNA Technologies), together with either shCTR or shSOS2-3434 (1 μg) by using DharmaFectDuo transfection reagents, and the transfected cells enriched by G418 selection (400 μg/ml; 60 h). Total cell lysates were prepared and subjected to immunoblotting to determine the expression level of endogenous proteins. To determine the effect of shPACR1-384 on PACR1 expression, PC6 cells were transfected with shCTR or shPACR1-384 (1.5 μg), and subjected to total RNA isolation using the RNeasy Mini kit (QIAGEN). Total RNA (2 μg) was used for reverse transcription using the Omniscript Reverse Transcription kit (QIAGEN) and rat PACR1 and β-actin levels determined by reverse transcription-polymerase chain reaction (RT-PCR) as described previously ([@B55]).

Rit-GTP Precipitation Assays
----------------------------

Glutathione transferase (GST) fusion proteins containing the Rit binding domain (RBD) of RGL3 (residues 610-709) were expressed in bacterial and purified, and Rit activation was assessed as described previously ([@B53]). Bound GTP-Rit was detected by immunoblot analysis using anti-FLAG monoclonal antibody as described previously ([@B53]; [@B56], [@B55]). It should be noted that that interexperimental differences in basal Rit-GTP levels make it difficult to compare absolute GTP-Rit levels in separate studies.

SOS GEF Activity Assay
----------------------

The fluoresce base GEF assay was performed as described previously for Epac and Rit ([@B56]). The catalytic fragment of human Sos1 (residue 564-1049) was expressed as a His-tagged fusion protein in BL21DE3 and purified by nickel affinity chromatography and gel filtration.

Immunoprecipitation and Phosphorylation Analysis
------------------------------------------------

The activation state of TrkA, Src, Shc1, and SOS was monitored by phosphotyrosine-specific immunoblotting after immunoprecipitation ([@B53]). In brief, transiently transfected PC6 cells were harvested, and whole cell lysates were prepared using kinase lysis buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 50 mM KF, 50 mM β-glycerolphosphate, 2 mM EGTA, pH 8.0, 1 mM Na~3~VO~4~, 1% Triton X-100, 10% glycerol, and 1× protease cocktail) and subsequently incubated with the appropriate antibody and 30 μl of protein G-Sepharose resin (GE Healthcare, Little Chalfont, Buckinghamshire, United Kingdom) at 4°C for 1--2 h with end-to-end rotation. After incubation, the resin was collected by centrifugation (10,000 rpm for 5 min at 4°C), washed four times with kinase lysis buffer, and the bound proteins were fractionated by SDS-polyacrylamide gel electrophoresis (PAGE) and subjected to immunoblot analysis with appropriate antibodies as described previously ([@B53]).

Neurite Outgrowth
-----------------

To examine the contribution of Shc1-Grb2-SOS signaling to PACAP38-mediated neuronal differentiation, neurite elongation analysis was performed as described previously ([@B53]). Neurite outgrowth was analyzed by counting 200 cells in 9 to 12 random fields at day 7 after initiation, and the percentage of neurite-bearing cells and neurite number per cell are presented as mean ± SD from three independent experiments performed in triplicate.

RESULTS
=======

Several Gα Pathways Activate Rit
--------------------------------

We recently demonstrated that PACAP38-mediated neuronal differentiation and cAMP response element-binding protein (CREB)-dependent transcription rely on activation of the Rit GTPase, which is regulated downstream of a novel G~s~α/cAMP/Epac-dependent signaling cascade ([@B56]; [@B12]). However, although endogenous Epac proteins were required for PACAP-mediated Rit activation, Epac1/2 did not directly activate Rit, suggesting that an additional factor(s) is involved in this regulatory cascade. Although PACAP-GPCR signaling is thought to primarily operate through a G~s~α-cAMP cascade, studies have reported PACAP38-mediated activation of other Gα family members ([@B38]). To determine whether these alternative pathways were involved in Rit signaling, PC6 cells were cotransfected with 3xFLAG-Rit-wild type (WT) and constitutively active G~i~α, G~q~α, and G~12~α. Coexpression of GTPase-deficient G~i2~αQ204L and G~q~αQ209L, but not G~12~αQ229L, resulted in Rit activation ([Figure 1](#F1){ref-type="fig"}A). Moreover, treatment of PC6 cells with PTX, an inhibitor of G~i~α signaling ([@B41]), potently suppressed PACAP38-mediated Rit activation ([Figure 1](#F1){ref-type="fig"}B). These data indicate that PACAP38-dependent Rit activation relies upon both G~i~α and G~s~α ([@B56]) signaling cascades.

![G~i~α and G~q~α signaling activates Rit. (A) PC6 cells transiently cotransfected with 3xFLAG-Rit-WT and either G~i2~αQ204L, G~q~αQ209L, or G~12~αQ229L, were serum starved (5 h) before the preparation of whole cell lysates. GTP-bound Rit levels were examined after GST-RGL3-RBD precipitation as described in *Materials and Methods*. (B) PC6 cells expressing 3xFLAG-Rit-WT were starved in serum-free DMEM for 5 h and subsequently pretreated with PTX (100 ng/ml for 30 min) or dimethyl sulfoxide before PACAP38 (10 nM) stimulation. Rit-GTP levels were assayed as described in A. The data are representative of the three individual experiments.](zmk0091094280001){#F1}

Src Is Required for PACAP38-mediated Rit Activation
---------------------------------------------------

Recent studies indicate that both G~i~α and G~s~α are stimulated in PACAP38-treated PC12 cells ([@B26]; [@B29]) and activate a Src-dependent signaling cascade to promote neurite outgrowth ([@B43]). To determine whether PACAP38-mediated Rit activation involves a similar pathway, we next examined whether Rit was regulated in a Src-dependent manner. Consistent with a role for Src in this cascade, expression of a dominant inhibitory Src mutant (DN-Src \[Src^K296R/Y528F^\]) suppressed PACAP38-mediated Rit activation, whereas expression of an activated Src mutant (CA-Src \[Src^Y529F^\]) alone resulted in strongly elevated Rit-GTP levels ([Figure 2](#F2){ref-type="fig"}A). Moreover, treatment with the Src inhibitor PP2 (10 μM), but not the inactive PP3 isomer (10 μM), potently inhibited PACAP38-mediated Rit activation ([Figure 2](#F2){ref-type="fig"}B).

![Src is required for PACAP38-cAMP-Epac-mediated Rit activation. (A) PC6 cells were transiently cotransfected with 3xFLAG-Rit-WT and CA-Src or DN-Src, allowed to recover for 36 h, serum starved for 5 h, and then stimulated with PACAP38 (10 nM). GTP-Rit levels were determined by GST-RGL3-RBD pull-down assay as described in *Materials and Methods*. (B) PC6 cells expressing FLAG-tagged Rit were serum starved for 5 h and pretreated with PP2 (10 μM), PP3 (10 μM), or dimethyl sulfoxide (DMSO) (vehicle) for 30 min before PACAP38 stimulation (10 nM). GTP-Rit levels were monitored by GST-RGL3-RBD pull-down. (C) PC6 cells were cotransfected with 3xFLAG-Rit-WT and DN-Src or empty vector in the presence or absence of CA-Epac2, or they were stimulated with 8-CPT-2-Me-cAMP (25 μM) as indicated. GTP-bound Rit levels were analyzed as described above. (D) PC6 cells were coexpressed with 3xFLAG-Rit-WT and CA-Epac2 after pretreatment with PP2 (10 μM), PP3 (10 μM), or vehicle DMSO, and GTP-Rit levels were analyzed as described above. (E) Rit-WT--transfected cells were serum starved (5 h) and pretreated with PP2 (10 μM), PP3 (10 μM), or DMSO for 30 min before stimulation with 8-CPT-2-Me-cAMP (25 μM). GTP-Rit levels were measured from whole cell lysates as described above. (F) Serum-starved PC6 cells cotransfected with 3xFLAG-Rit-WT and either Src-S17A, the indicated amount of CA-Src-S17A, or empty vector (EV), were stimulated with PACAP38 (10 nM). GTP-Rit levels were analyzed as described above. The data in each panel are representative of the results from a minimum of three independent experiments.](zmk0091094280002){#F2}

PACAP38-mediated Rit activation involves a cAMP-Epac signaling cascade ([@B56]). Consistent with a role for Src downstream of Epac in this pathway, expression of DN-Src was found to potently inhibit Rit activation after stimulation of PC6 cells with the Epac-selective cAMP analog 8-CPT-2′-*O*-Me-cAMP or coexpression with a constitutively active Epac2 mutant (CA-Epac2; [Figure 2](#F2){ref-type="fig"}C). Moreover, treatment with PP2, but not PP3, inhibited both CA-Epac2- ([Figure 2](#F2){ref-type="fig"}D) and 8-CPT-2′-*O*-Me-cAMP ([Figure 2](#F2){ref-type="fig"}E)-mediated Rit activation. Together, these data suggest that Src plays a central role in PACAP38-dependent Rit activation.

PKA-dependent phosphorylation of Src at Ser^17^ contributes to the activation of Rap1 GTPases in response to both elevated cAMP and NGF stimulation in PC12 cells ([@B43]). As seen in [Figure 2](#F2){ref-type="fig"}F, expression of Src^S17A^ (a Src mutant incapable of being phosphorylated by PKA) had no effect on PACAP38-mediated Rit activation. Furthermore, expression of an activated Src^S17A^ mutant (CA-Src^Y529F/S17A^) resulted in potent Rit activation ([Figure 2](#F2){ref-type="fig"}F). Thus, although Src signaling is critical in PACAP-mediated Rit activation, PKA-mediated Src phosphorylation is not required.

Involvement of TrkA in PACAP38-mediated Rit Activation
------------------------------------------------------

PACAP has been found to stimulate Trk receptor tyrosine kinase activity in a Src-dependent cross-talk cascade to promote neuronal survival ([@B28],[@B29]). To investigate whether the Trk receptor was required for PACAP38-mediated Rit activation, we made use of nnr5 cells, a PC12 cell variant that fails to express TrkA ([Figure 3](#F3){ref-type="fig"}D; [@B14]). As seen in [Figure 3](#F3){ref-type="fig"}A, treatment with 8-CPT-2′-*O*-Me-cAMP, PACAP38, or overexpression of CA-Epac2 failed to promote elevated GTP-Rit levels of nnr5 cells. The deficiency in Rit activation can be traced to the lack of TrkA receptor, because expression of the wild-type receptor in nnr5 cells restored PACAP38- ([Figure 3](#F3){ref-type="fig"}B), 8-CPT-2′-*O*-Me-cAMP-, and CA-Epac2 ([Figure 3](#F3){ref-type="fig"}C)-mediated Rit activation. Thus, PACAP38-dependent Rit activation requires Trk receptor.

![TrkA receptor activity is required for PACAP38- and Epac-mediated Rit activation. (A) nnr5 cells expressing 3xFLAG-Rit-WT were cotransfected with or without CA-Epac2 and serum starved before exposure to PACAP38 (10 nM) or 8-CPT-2-Me-cAMP (25 μM). GTP-Rit levels were analyzed as described in *Materials and Methods*. (B) nnr5 cells were transfected with 3xFLAG-Rit-WT in the presence or absence of TrkA receptor (WT-TrkA), subjected to serum starvation (5 h) and stimulated with PACAP38 (10 nM). Cellular GTP-Rit levels were analyzed using GST-RGL3-RBD pull-down as described above. Note that TrkA expression restored PACAP-mediated Rit activation. (C) nnr5 cells expressing 3xFLAG-Rit-WT were transfected with CA-Epac2 and/or WT-TrkA as indicated, and stimulated with 8-CPT-2-Me-cAMP (25 μM) after serum starvation (5 h). GTP-bound Rit levels were determined by RGL3-RBD pull-down. The results in A--C are representative of three to five independent experiments. (D) Total cell lysates (100 μg) were prepared from PC12, PC6, nnr5, NIH-3T3 and Madin-Darby canine kidney (MDCK) cells, subjected to fractionation by SDS-PAGE, and examined by immunoblotting. Note that nnr5, NIH-3T3, and MDCK cells fail to express detectable TrkA.](zmk0091094280003){#F3}

PACAP38-mediated TrkA Activation Requires Src
---------------------------------------------

PACAP38 effects are mediated by PACR1 receptors expressed in PC12 cells, including PACR1-mediated transactivation of Trk neurotrophin receptors ([@B29]; [@B48]). To confirm that PACAP38-dependent Rit activation requires PACR1 in PC6 cells, the endogenous receptor was silenced by transfection with a selective short hairpin (sh)RNA vector (shPACR1-384; [Figure 4](#F4){ref-type="fig"}A). Partial receptor loss impaired PACAP38-mediated Rit activation ([Figure 4](#F4){ref-type="fig"}B). To examine whether PACAP38-dependent Rit signaling involves GPCR-mediated transactivation, anti-phosphotyrosine Western blotting was used to analyze immunoprecipitated TrkA receptors. Activated TrkA receptors were observed within 10 min of PACAP38 stimulation and remained active for at least 1 h ([Figure 4](#F4){ref-type="fig"}C). PACAP-mediated TrkA activation was partially inhibited by PACR1 receptor silencing, supporting a pathway in which PACAP-mediated Trk transactivation contributes to Rit signaling ([Figure 4](#F4){ref-type="fig"}C). Application of the Src inhibitor PP2, but not PP3, resulted in a marked decrease in the level of tyrosine phosphorylated TrkA receptors elicited by PACAP38 ([Figure 4](#F4){ref-type="fig"}D). Phosphorylated TrkA levels were also inhibited by pretreatment with either the G~i~α inhibitor PTX or the direct adenyl cyclase inhibitor ddA, before PACAP38 stimulation ([Figure 4](#F4){ref-type="fig"}D). Cumulatively, these data suggest that regulation of TrkA by PACAP38/cAMP/Epac signaling may be mediated by a Src family kinase.

![PACAP38-mediated Rit activation involves PACR1-dependent TrkA transactivation. (A) PC6 cells were transfected with either shCTR or shPACR1-384 and then subjected to G418 (400 μg/ml) selection for 60 h. Total RNA was isolated and RT-PCR used to monitor PACR1 silencing. (B) PC6 cells cotransfected with 3xFLAG-Rit-WT and either shCTR or shPACR1-384 were starved in serum-free DMEM (5 h) and stimulated with PACAP38 (20 nM). Cell lysates were prepared and subjected to GST-RGL3-RBD pull-down. (C) PC6 cells transfected with either shCTR or shPACR1-384 were enriched with G418 (400 μg/ml; 60 h) and serum starved (5 h) before stimulation with either PACAP38 (20 nM) or NGF (100 ng/ml). Total cell lysates (1 mg) were prepared and subjected to anti-TrkA immunoprecipitation. Anti-phosphotyrosine specific immunoblotting was used to detect activate TrkA, and the stripped membrane was reprobed with anti-TrkA antibody to demonstrate equal loading. (D) PC6 cells were pretreated with PP2 (10 μM), PP3 (10 μM), PTX (100 ng/ml), ddA (50 μM), or dimethyl sulfoxide (DMSO); stimulated with PACAP38 (20 nM); and total cell lysates were prepared. NGF stimulation (100 ng/ml) served as positive control. Endogenous TrkA was immunoprecipitated (1 mg of total cell lysate) and activated receptor identified by anti-phosphotyrosine immunoblotting. (E) PC6 cells were transfected with c-Src-WT in the presence or absence of CA-Epac2, serum starved, and then stimulated with PACAP38 (10 nM), EGF (100 ng/ml), or not treated (phosphate-buffered saline \[PBS\]). Total lysates (500 μg) were subjected to anti-c-Src immunoprecipitation, and active Src levels were examined by phosphotyrosine-specific immunoblotting. Note that both PACAP38 and CA-Epac2 result in c-Src activation. (F) PC6 cells expressing c-Src-WT were starved for 5 h before stimulation with 8-CPT-2-Me-cAMP (25 μM) for 5, 10, or 30 min, and the phosphotyrosine levels of Src determined as described above. (G) PC6 cells expressing c-Src-WT were starved (5 h) and pretreated with or without PTX (100 ng/ml; 30 min) before stimulation with either PACAP38 (20 nM; 10, 30, or 60 min) or CTX (2.5 μg/ml; 10, 30, or 60 min). Total cell lysates were prepared and analyzed for Src tyrosine phosphorylation analysis as described above. The data in each panel are representative of the results from a minimum of three independent experiments.](zmk0091094280004){#F4}

Src family kinases have been implicated as mediators of receptor tyrosine kinase transactivation by several G protein-coupled agonists, including PACAP38 ([@B35]; [@B28]; [@B7]). If a Src family kinase was involved in the activation of Trk receptors by PACAP38, we reasoned that Src should not only be activated after PACAP38 stimulation of PC6 cells but also operate downstream of activated Epac. Treatment of Src expressing PC6 cells with PACAP38 resulted in a marked and time-dependent increase in the level of tyrosine phosphorylated Src, as measured by anti-phosphotyrosine immunoblotting of precipitated Src kinases ([Figure 4](#F4){ref-type="fig"}E). The level of tyrosine phosphorylated Src was also increased in a dose-dependent manner by cotransfected CA-Epac2 ([Figure 4](#F4){ref-type="fig"}E) or by treatment with 8-CPT-2′-*O*-Me-cAMP ([Figure 4](#F4){ref-type="fig"}F), PACAP38- ([Figure 4](#F4){ref-type="fig"}, E and G) and CTX (a known G~s~α activator; [Figure 4](#F4){ref-type="fig"}G), whereas both PACAP38- and CTX-mediated Src activation was inhibited by PTX ([Figure 4](#F4){ref-type="fig"}G), implicating Src activation in PACAP transactivation signaling.

Tyrosine 499 of TrkA Is Required for PACAP-mediated Rit Activation
------------------------------------------------------------------

On activation Trk receptors become phosphorylated on five tyrosine residues within the intracellular domain and use these residues to recruit, phosphorylate, and activate a variety of intracellular signaling proteins ([@B21]). To identify the site(s) required for TrkA-mediated Rit activation, we tested two TrkA point mutants defective in binding to specific signaling proteins. As seen in [Figure 5](#F5){ref-type="fig"}A, NGF stimulation of NIH-3T3 cells coexpressing FLAG-tagged wild-type Rit and either wild-type TrkA or TrkA^Y794F^ resulted in potent Rit activation as monitored by GST-RGL3 pull-down analysis ([Figure 5](#F5){ref-type="fig"}A, lanes 2 and 4). However, the TrkA^Y499A^ mutant failed to promote Rit activation, indicating that this residue is required the regulation of downstream Rit signaling. NIH-3T3 cells lack endogenous TrkA receptor ([Figure 3](#F3){ref-type="fig"}D), and NGF-dependent Rit activation required a functional receptor, because coexpressed TrkC, which is not activated by NGF ([@B50]), failed to restore Rit activation ([Figure 5](#F5){ref-type="fig"}A, lane 5). Similar results were seen following PACAP38 stimulation, in which expression of either WT-TrkA or TrkA^Y794F^, but not TrkA^Y499F^, restored Rit activation ([Figure 5](#F5){ref-type="fig"}B). Thus, tyrosine 499 of TrkA is critical for both NGF- and PACAP-mediated Rit activation.

![PACAP/Epac-dependent Rit activation and TrkA transactivation require TrkA^Y499^. (A and B) NIH-3T3 cells were transfected with 3xFLAG-Rit-WT in the presence or absence of TrkA-WT, TrkA-Y499F, TrkA-Y794F, or TrkC-WT as control (A) and then serum starved (5 h) before stimulation with NGF (100 ng/ml; 15 min) or PACAP38 (10 nM; 20 min). GTP-bound Rit levels were determined as described in *Materials and Methods*. NIH-3T3 (C and E) or PC6 (D) cells expressing either HA-TrkA-Y499F or -Y794F were stimulated with PACAP38 (20 nM; 20 min) or 8-CPT-2-Me-cAMP (25 μM; 30 min \[E\] or as indicated \[D\]) after starvation with serum-free DMEM (5 h). Total cell lysates were subjected to anti-TrkA or anti-HA immunoprecipitation and TrkA activation examined by anti-phosphotyrosine immunoblotting. (F) NIH-3T3 cells expressing HA-TrkA-WT or HA-TrkA-Y794F were starved for 5 h and subsequently pretreated with PTX (100 ng/ml), ddA (50 μM), PP2 (10 μM), or Rp-cAMP (50 μM) for 30 min before stimulation with PACAP38 (20 nM) for 20 min. NIH-3T3 cells expressing HA-TrkA-WT served as control. TrkA activation was analyzed as described in A. (G) Epac1 silencing attenuates PACAP38-Epac signaling but not NGF-mediated Src and TrkA activation. PC6 cells were transfected with HA-TrkA-WT and C-Src-WT in presence of either shCTR or shEpac1--1501 and subjected to G418 (400 μg/ml) selection to enrich for transfected cells. Note that PC6 cells express Epac1 but not Epac2 ([@B56]). Cells were then starved with serum-free DMEM for 5 h before be stimulated with PACAP38 (20 nM; 10, 30, or 60 min), 8-CPT-2-Me-cAMP (25 μM; 10, 30, or 60 min), CTX (2.5 μg/ml; 10, 30, or 60 min), or NGF (100 ng/ml; 15 or 30 min). Total lysates were subsequently prepared, subjected to anti-TrkA (2 μg) and anti-C-Src (4 μg) immunoprecipitation, and resolved by SDS-PAGE, and then the phosphotyrosine levels of TrkA and Src were examined by phosphotyrosine-specific immunoblotting. The results are representative of three or four independent experiments.](zmk0091094280005){#F5}

To explore whether these same specific tyrosine residues are required for PACAP38-mediated TrkA transactivation, NIH-3T3 cells expressing either TrkA^Y499F^ or TrkA^Y794F^ were subject to PACAP38 stimulation and TrkA activity was monitored by anti-phosphotyrosine immunoblotting of the precipitated receptor. As seen in [Figure 5](#F5){ref-type="fig"}, C and E, PACAP38 signaling resulted in robust phosphorylation of Trk^Y794F^ but failed to stimulate the TrkA^Y499F^ mutant receptor. As expected, 8-CPT-2′-*O*-Me-cAMP--mediated Epac activation also failed to promote phosphorylation of the TrkA^Y499F^ mutant but promoted robust TrkA^Y794F^ phosphorylation ([Figure 5](#F5){ref-type="fig"}, D and E). Together, these data suggest that in addition to being critical for Rit activation, PACAP-dependent TrkA transactivation requires an intact Tyr^499^ phosphotyrosine docking site.

PACAP-mediated TrkA activation was inhibited by pharmacological blockade of G~i~α (PTX), adenyl cyclase (ddA), or Src (PP2) but not protein kinase A (Rp-cAMP), supporting a role for cAMP/Src signaling in transactivation ([Figure 5](#F5){ref-type="fig"}F). In addition, PACAP-, 8-CPT-2′-*O*-Me-cAMP-, and CTX-dependent TrkA stimulation, but importantly not NGF-mediated receptor activation, was inhibited by Epac1 silencing ([Figure 5](#F5){ref-type="fig"}G). In keeping with a PACR1-dependent transactivation cascade in which Epac functions upstream of Src family kinases, Epac1 silencing resulted in a dramatic inhibition of PACAP-, 8-CPT-2′-*O*-Me-cAMP-, and CTX-mediated Src activation, as measured by anti-phosphotyrosine immunoblotting of precipitated Src kinases ([Figure 5](#F5){ref-type="fig"}F). Together, these data suggest that PACAP-dependent TrkA transactivation involves a cAMP/Epac/Src signaling cascade.

PACAP-mediated Rit Activation Involves SOS
------------------------------------------

On TrkA activation phosphorylated Tyr^499^ provides a recruitment site for both the Shc/Grb2/SOS complex to promote Ras activation, and FRS2, which associates with the adapter protein Crk/RapGEF C3G complex to stimulate Rap GTPase signaling ([@B21]; [@B50]). To directly assess the contribution of these GEFs to Rit activation, we used shRNAi-mediated silencing ([@B11]) to selectively knock down endogenous C3G and SOS1/2 in PC6 cells. As shown in [Figure 6](#F6){ref-type="fig"}A, both shC3G-128 and shC3G-2739, but not shCTR (control shRNA with no predicted target in the rat genome; [@B54]), silenced C3G in PC6 cells. However, C3G knockdown had no obvious effect on either PACAP38- or NGF-mediated Rit activation ([Figure 6](#F6){ref-type="fig"}B), suggesting that another GEF is required.

![C3G is not required for Rit activation, but the Shc1/Grb2 adaptors contribute to PACAP38-dependent neuronal differentiation. (A) Anti-C3G immunoblotting demonstrates silencing of endogenous C3G after transfection with shC3G-128 and shC3G-2739 but not shCTR, in PC6 cells. (B) PC6 cells expressing 3xFLAG-Rit-WT were cotransfected with either shCTR or shC3G-2739 and then stimulated with PACAP38 (20 nM) or NGF (100 ng/ml). GTP-bound Rit levels were determined by GST-RGL3-RBD pull-down. (C) PC6 cells expressing Shc1-WT-3xFLAG were either cotransfected with CA-Src, CA-Epac2, or stimulated with PACAP38 (20 nM) or 8-CPT-2-Me-cAMP (25 μM) after serum starvation. Total cell lysates were prepared, subjected to anti-FLAG immunoprecipitation (500 μg), and the levels of phosphorylated Shc1 determined by anti-phosphotyrosine immunoblotting. (D) Neurite outgrowth was initiated by cotransfection of PC6 cells with 3xFLAG-Rit-Q79L and either empty-3xFLAG vector, Shc1-FFF-3xFLAG, or Grb2-R86K-3xFLAG, or by the addition of NGF (100 ng/ml) or PACAP38 (20 nM). Cells were replated (1:4 dilution) after transfection and enriched by G418 (400 μg/ml) selection. Neurite outgrowth was analyzed at day 7, and the percentage of neurite-bearing cells (top) and neurite number per cell (bottom) calculated as described in *Materials and Methods*. The results were represented as mean ± SD from three independent experiments performed in triplicate. (E) PC6 cells were starved in serum-free DMEM (10 h) and then pretreated with PP2 (10 μM), PP3 (10 μM), Rp-cAMP (50 μM), ddA (50 μM), PTX (100 ng/ml), or dimethyl sulfoxide (DMSO, vehicle control) for 30 min before stimulation with or without PACAP38 (20 nM) for 20 min. Total cell lysates (500 μg) were prepared and subjected to either anti-SOS1 or anti-SOS2 immunoprecipitation, and active SOS levels were determined by anti-phosphotyrosine immunoblotting. (F) PC6 cells were transfected with 3xFLAG-Rit-WT in the presence or absence of either FLAG-Shc1--3F (FFF) or Myc-Grb2-R86K and starved for 5 h before stimulation with either PACAP38 (20 nM) or NGF (100 ng/ml) as indicated. GTP-Rit levels were examined as described in *Materials and Methods*. The results are representative of three independent experiments.](zmk0091094280006){#F6}

The activation of downstream signaling pathways by TrkA is complex, but recruitment to the active receptor often requires the Shc1 and Grb2 adaptor proteins and results in tyrosine phosphorylation of Shc1 and both SOS1 and SOS2 GEFs ([@B34]; [@B50]). As seen in [Figure 6](#F6){ref-type="fig"}C, PACAP38 stimulation resulted in rapid Shc1 phosphorylation. Furthermore, treatment with 8-CPT-2′-*O*-Me-cAMP, expression of CA-Src, or CA-Epac2, also elevated the levels of tyrosine phosphorylated Shc1 in PC6 cells ([Figure 6](#F6){ref-type="fig"}C). Expression of dominant-negative adaptor proteins has been shown to inhibit both downstream TrkA signaling and NGF-dependent neuritogenesis in PC12 cells, by disrupting the recruitment and activation of a variety of intracellular signaling proteins to the active receptor ([@B57],[@B58]; [@B39]). Consistent with these earlier studies ([@B63]), expression of dominant-negative Shc1 (Shc1-FFF), or a Grb2 (Grb2-R86K) mutant that disrupts formation of the Shc-Grb2 complex, was found to significantly inhibit both neurite outgrowth and neurite number per cell body in NGF-stimulated PC6 cells ([Figure 6](#F6){ref-type="fig"}D). Despite the fact that PACR1 signaling does not rely upon adaptor recruitment, expression of these mutants also inhibited PACAP38-mediated PC6 cell neurite outgrowth and neurite number, but importantly it had no effect on neuronal differentiation induced by expression of activated Rit ([Figure 6](#F6){ref-type="fig"}D). As expected, expression of these adapter mutants inhibited NGF-dependent Rit stimulation, but importantly, it also disrupted PACAP38-mediated Rit activation ([Figure 6](#F6){ref-type="fig"}F).

PACAP38 stimulation also resulted in the generation of tyrosine phosphorylated SOS1 and SOS2 ([Figure 6](#F6){ref-type="fig"}E). Moreover, pretreatment of PC6 cells with PP2, but not PP3, resulted in a marked decrease in the levels of tyrosine phosphorylated SOS1 and SOS2 after PACAP38 stimulation. Phosphorylated SOS1/2 levels were also inhibited by pretreatment with either the G~i~α inhibitor PTX, or the direct adenylate cyclase inhibitor ddA, but not the PKA inhibitor Rp-cAMP ([Figure 6](#F6){ref-type="fig"}E). Together, these studies suggest that both NGF- and PACAP38-mediated Rit activation involves the adaptor-dependent recruitment of SOS by TrkA.

We next examined whether SOS1/2 contributed to PACAP38-dependent Rit activation. As expected, expression of constitutively active SOS1 resulted in a dose-dependent stimulation of Rit-GTP levels ([Figure 7](#F7){ref-type="fig"}A). To extend this analysis, two approaches were used to silence the SOS1 and SOS2 GEFs, which are both endogenously expressed in PC6 cells ([Figure 3](#F3){ref-type="fig"}D). Although shSOS2-3434 proved effective at knocking down endogenous SOS2, shRNA vectors proved ineffective at silencing SOS1 ([Figure 7](#F7){ref-type="fig"}B). Instead, transfection with a synthetic siRNA pool was used to selectively reduce SOS1 expression and the combined introduction of the siSOS1 pool and shSOS2-3434 to PC6 cells resulted in the knockdown of both SOS family members ([Figure 7](#F7){ref-type="fig"}C). After silencing of either SOS1 or SOS2 alone failed to inhibit PACAP38-mediated Rit activation (data not shown), the simultaneous knockdown of both SOS1/2 GEFs potently inhibited PACAP38- and NGF-mediated Rit activation ([Figure 7](#F7){ref-type="fig"}D), suggesting that SOS1/2 GEFs are involved in TrkA-mediated Rit activation.

![SOS1/2 silencing inhibits PACAP38- and NGF-mediated Rit activation in PC6 cells, but SOS1 does not function as an in vitro RitGEF. (A) PC6 cells were cotransfected with 3xFLAG-Rit-WT and CA-SOS1, and cell lysates prepared after starvation in serum-free DMEM (5 h). GTP-Rit levels were determined as described in *Materials and Methods*. (B) PC6 cells expressing shSOS1-4316, shSOS2-3434, or shCTR were enriched by G418 selection (400 μg/ml), and the expression of SOS1 and SOS2 determined by immunoblotting. Note that shSOS2-3434 silences SOS2. (C) PC6 cells were cotransfected with shCTR or siSOS1 (20 nmol) together with shCTR or shSOS2-3434, and enriched by G418 (400 μg/ml; 60 h) selection. Cell lysates were prepared and subjected anti-SOS1 or anti-SOS2 immunoblotting. (D) PC6 cells expressing 3xFLAG-Rit-WT were cotransfected with either siSOS1/shSOS2--3434 or shCTR/shCTR as control and stimulated with PACAP38 (20 nM) or NGF (100 ng/ml). Total cell lysates were subjected to GST-RGL3-RBD precipitation and levels of GTP-Rit determined as described in *Materials and Methods*. (E) 200 nM Rit (left) or H-Ras (right) loaded with the fluorescent GDP analogue mGDP were incubated alone (open circles), in the presence of 200-fold excess unlabeled GDP (closed squares) or in the presence of unlabeled GDP and 500 nM Sos (open squares). The time-dependent decrease in fluorescence intensity monitors the exchange of protein bound mGDP for GDP. Note that in the absence of excess GDP the G protein nucleotide complex is stable. (F) Schematic diagram of the putative PACAP-Epac-Src-TrkA-SOS-Rit signal transduction cascade. The sites of action of various pharmacological inhibitors (⊣), selective activators (→), and the targets of shRNA silencing reagents (•) are indicated.](zmk0091094280007){#F7}

To determine whether SOS functions as a direct RitGEF, the catalytic domain of human SOS1 was incubated with fluorescent mGDP-loaded Rit or H-Ras in the presence of excess unlabeled guanosine diphosphate (GDP), and the exchange of guanine nucleotides was followed in real time as a decrease in fluorescence ([@B49]). As shown in [Figure 7](#F7){ref-type="fig"}E, when these rates were compared with the intrinsic exchange rate for mGDP-Rit measured in the same experiment, no difference was seen. As expected, SOS1 exhibited in vitro catalytic activity toward H-Ras ([@B45]), demonstrating the utility of the assay ([Figure 7](#F7){ref-type="fig"}E). Thus, although RNAi methods indicate that SOS proteins are required for Rit activation, the ability of SOS to function as an in vitro Rit GEF could not be proven.

DISCUSSION
==========

Neurotrophic signaling cascades regulate a wide range of nerve cell functions, including differentiation, axonal and dendritic morphology, and survival, and they contribute to aspects of learning and memory. Although signaling through the Trk receptor tyrosine kinase family plays crucial roles in these regulatory processes ([@B50]), it is clear that additional cellular factors contribute prominently to these diverse biological effects. PACAP is widely expressed in the nervous system, and although it has been shown to promote neurotrophic signaling in many neuronal populations, the specific molecular pathways directing these actions remain incompletely characterized. Here we describe a novel signaling mechanism which contributes to the ability of PACAP38 to promote neurotrophic effects. Through cross-talk with Trk receptor tyrosine kinases, PACAP is capable of activating the Rit GTPase, to promote differentiation. This mechanism explains a gap in our understanding of Rit activation in addition to identifying a novel transactivation-dependent neuronal signaling cascade ([Figure 7](#F7){ref-type="fig"}F).

A conserved characteristic of GPCR-dependent RTK transactivation is the requirement for tyrosine phosphorylation of the targeted growth factor receptor ([@B35]; [@B67]; [@B7]). Previous work found that PACAP stimulation results in phosphorylation of tyrosine signaling sites on TrkA but that the specific phosphotyrosine docking sites and activation of downstream signaling pathways had not been characterized ([@B28],[@B29]; [@B10]). Using site-directed TrkA mutants ([Figure 5](#F5){ref-type="fig"}), RNAi silencing methods ([Figures 4](#F4){ref-type="fig"}[](#F5){ref-type="fig"}[](#F6){ref-type="fig"}--[7](#F7){ref-type="fig"}), and the expression of dominant-negative adaptor mutants ([Figure 6](#F6){ref-type="fig"}), we implicate the recruitment and activation of a SOS/Shc-Grb2 adaptor complex to the Y^499^ phosphotyrosine docking site of TrkA in Rit activation after either NGF stimulation or in PACAP-directed transactivation ([Figure 7](#F7){ref-type="fig"}F). However, in vitro biochemical analysis failed to demonstrate that SOS1 functions as a direct RitGEF ([Figure 7](#F7){ref-type="fig"}E). These studies are complicated by the high intrinsic rate of guanine nucleotide exchange of recombinant Rit1-211 (18 residue C-terminal truncation), which rivals that seen in SOS catalyzed H-Ras nucleotide exchange reactions ([Figure 7](#F7){ref-type="fig"}E). Analysis of in vivo Rit activation is inconsistent with endogenous protein displaying rapid uncatalyzed nucleotide exchange. Basal GTP-bound Rit levels are low and ligand stimulation results in a rapid increase in GTP-Rit levels in a variety of cell systems ([@B1], [@B2]; [@B53]; [@B56]; [@B30]). Thus, it is possible that removal of the Rit C terminus, which is required for bacterial protein expression ([@B52]), destabilizes nucleotide binding. Addressing this issue is an important future goal and will require the generation of stable full-length Rit in sufficient quantities to repeat these nucleotide exchange assays.

Assembly of a phosphotyrosine-specific signaling complex at TrkA^Y499^ is required for NGF-dependent neuronal differentiation ([@B42]; [@B50]). Importantly, previous studies have shown that Rit signaling is necessary for both NGF- and PACAP-dependent neurite elongation in pheochromocytoma cells ([@B53]; [@B56]) and must be factored into models for neurotrophin-mediated neuronal differentiation ([@B48]; [@B12]). However, the cellular role of Rit downstream of these two receptors seems to differ. Rit has been shown to regulate both extracellular signal-regulated kinase and p38 MAP kinase signaling after NGF stimulation ([@B53]), but only PACAP-mediated p38 kinase activation ([@B56]). This difference is particularly striking because data presented here indicates that a Trk receptor signaling complex directs Rit activation after exposure to either ligand ([Figures 3](#F3){ref-type="fig"}[](#F4){ref-type="fig"}[](#F5){ref-type="fig"}[](#F6){ref-type="fig"}--[7](#F7){ref-type="fig"}) and that the kinetics of Rit activation are similar after either PCAP38 or NGF stimulation ([@B53]; [@B56]). What might account for these differences? A growing literature indicates that the organization of higher order signaling complexes is a common mechanism to confer specificity to cellular signaling. For example, Ras and Rap1 GTPase signaling pathways are selectively activated by the recruitment of distinct regulatory proteins to Trk receptors ([@B62]; [@B50]). The nature of such a signaling complex may be controlled not only by the selective activation of phosphotyrosine docking sites on TrkA but also by interaction of TrkA with accessory binding partners, such as the p75 receptor ([@B50]), human tumorous imaginal disk 1 ([@B33]), ARMS/Kidins220 ([@B3]), or perhaps through direct interactions with the PACR1 as recently described for transactivation by the extracellular signal-regulated kinase-1 receptor ([@B3]; [@B7],[@B8]). Ongoing studies seek to determine whether Trk coreceptor binding contributes to the specificity of Rit-mediated downstream signaling.

Previous work established a role for Src-family kinases in Trk receptor transactivation signaling. Consistent with a role for a Src kinase in PACAP-mediated Rit activation, expression of activated Src was sufficient to induce Rit activation ([Figure 2](#F2){ref-type="fig"}A). Furthermore, expression of dominant-negative Src or pharmacological blockade of Src kinase signaling inhibits both PACAP- and Epac-mediated Rit activation ([Figure 2](#F2){ref-type="fig"}) and PACAP-stimulated TrkA tyrosine phosphorylation ([Figure 4](#F4){ref-type="fig"}D). The molecular mechanisms by which GPCR signaling promotes Src activation remain poorly understood but both G~i~α and G~s~α have been found to associate with and stimulate Src activity ([@B36]). Interestingly, Kim *et al.* have identified a direct interaction between Rit and both G~o~α and G~s~α ([@B25]), suggesting that a higher order signaling complex containing Gα, Src, and Rit might contribute to transactivation. Similar to Rit activation, Epac-mediated c-Jun NH~2~-terminal kinase kinase activation requires a conserved Ras exchange motif (REM) domain but does not involve the RapGEF domain ([@B19]). It will be important to determine whether REM, or another domain within Epac, directs Src activation. Direct phosphorylation of TrkA by Src family kinases has been demonstrated in vitro ([@B64]; [@B46]), and our studies suggest that Src may lead to selective activation of TrkA. Although the activation status of individual tyrosine residues in TrkA was not directly examined in this study, we found a critical role for Y^499^ in both PACAP38-mediated Rit activation ([Figure 5](#F5){ref-type="fig"}B) and to overall TrkA tyrosine phosphorylation ([Figure 5](#F5){ref-type="fig"}, C and D). The importance of Y^499^ to the recruitment and activation of the Shc/Grb2/SOS1/2 regulatory complex is well established ([@B50]); however, its significance to PACAP-mediated TrkA activation is less clear. Several mechanisms for Src family kinase-mediated regulation of Ras GTPase signaling have been described previously. These include direct phosphorylation and activation of either individual GEFs or their adaptor proteins and modulation of GAP protein activity ([@B13]; [@B70]; [@B4]; [@B18]; [@B23]; [@B40]). In addition, the docking of Src family members to a TrkA receptor signaling complex might allow these kinases to regulate Trk catalytic activity, or to direct Trk receptor trafficking. Further studies are needed to fully characterize the role for Src kinases in both PACAP-mediated Rit activation and TrkA transactivation.

In conclusion, our results demonstrate that PACAP38-dependent Rit activation involves transactivation of the TrkA receptor. In this cascade, cAMP/Epac signaling regulates Src kinase-dependent phosphorylation of TrkA^Y499^ that leads to Rit activation, probably via the recruitment and activation of a cellular GEF, perhaps SOS ([Figure 7](#F7){ref-type="fig"}F). These studies further highlight the importance of transactivation in GPCR signaling. This is particularly true in the case of PACAP/Trk signaling, with a variety of studies indicating that transactivation plays a critical role in PACAP-mediated neuronal differentiation and survival signaling ([@B28]; [@B7]). PACAP and PACR1 have established signaling roles in the regulation of complex behavioral and neurological effects ([@B65]; [@B59]; [@B17]). Moving forward, it will be necessary to consider the role of PACAP-mediated Trk transactivation and the contribution of Rit signaling to these physiological processes.
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8-CPT-2-Me-cAMP

:   8-(*p*-chlorophenylthio)-2′-*O*-methyl-adenosine-3′,5′-cyclic monophosphate

C3G

:   C3G guanine-nucleotide exchange factor

CTX

:   cholera toxin

ddA

:   2′,5′-dideoxyadenosine

Epac

:   exchange protein activated by cyclic AMP

GPCR

:   G protein-coupled receptor

NGF

:   nerve growth factor

PTX

:   pertussis toxin

PACAP

:   pituitary adenylyl cyclase-activating peptide

PACR1

:   pituitary adenylyl cyclase-activating peptide receptor type I

PKA

:   protein kinase A

Rp-cAMP

:   adenosine 3′,5′-cyclic monophosphorothioate, Rp-isomer

RTK

:   receptor tyrosine kinase

SOS

:   son of sevenless.
